Receptor Profile
Receptor Actions
Effect Profile
Curated + 7 ReportsStrong focus and stimulation with low euphoria and anxiety/jitters
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Tolerance appears to build gradually with frequent daily use and decays over weeks after cessation, based on user patterns with racetams generally; consider cycling (e.g., 5 days on, 2 off, or 2–4 weeks on, 1–2 weeks off) to maintain effect and reduce escalation. Data are anecdotal.
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 7 experience reports (7 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 3
Adverse Effects 0
Real-World Dose Distribution
62K DosesFrom 14 individual dose entries
Oral (n=14)
Form / Preparation
Most common forms and preparations reported
Harm Reduction
drugs.wiki• Product misrepresentation is a known risk with research chemicals; verify identity and weigh doses precisely with a milligram scale. TripSit warns RCs are often mislabelled and that initial doses should be conservative until identity and potency are established.
• Start low and divide doses to limit jitteriness and GI upset; several community threads describe stimulant-like effects and stomach issues at higher single doses. Label dosing devices (scoops) are unreliable; a scale is recommended.
• Avoid dosing late in the day; users commonly report insomnia or sleep disruption when taken in the afternoon or evening.
• Combining with choline donors can reduce racetam‑associated headaches in some but may also increase stimulation, anxiety, or headaches if choline load is excessive; adjust choline slowly if used.
• Concurrent use with CNS depressants (opioids, benzodiazepines, sedatives) can increase CNS depression risk per DrugBank’s interaction listings; avoid or use only under medical oversight.
• Limit stacking with other stimulants (e.g., high caffeine, modafinil) to reduce risk of tachycardia, anxiety, and insomnia; space compounds and test combinations cautiously. General stimulant HR principles apply.
• Some reports suggest racetams can potentiate MDMA’s acute effects and alter the comedown; given uncertainty and interindividual variability, avoid this combination or proceed only with strong experience and conservative dosing.
• Pharmacokinetic human data are limited in open sources; treat use in renal impairment, pregnancy, or breastfeeding as higher risk and consider avoidance or medical guidance due to uncertain elimination and lack of safety data. DrugBank lists Oxiracetam as investigational with sparse PK fields.
• Take with food and adequate hydration to mitigate nausea or GI discomfort reported anecdotally.
• Do not rely on subjective clarity to judge fitness to drive or operate machinery; stimulant-like effects can mask impairment or cause over‑arousal. Follow general driving HR advice and avoid until individual response is known.
References
Cited References
Drugs.wiki References
- DrugBank: Oxiracetam (DB13601)
- TripSit Wiki: Research Chemicals – risks, misrepresentation, dosing cautions
- Drugs-Forum Wiki: Oxiracetam (synonyms/overview)
- Reddit r/Nootropics: First Time Racetam Use (half-life/choline anecdote)
- Reddit r/StackAdvice: Integrating Oxiracetam & Centrophenoxine (stimulation, headache)
- Bluelight: Racetams and MDxx potentiation discussion
- Reddit r/NooTopics: Pramiracetam side effects thread (scale admonition applicable to noots)
- DrugWise: General stimulants risk guidance (anxiety/panic; HR context)
- DrugWise: UK drug-driving guidance (HR context re impairment)